AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 528201: Benzoic acid, 2-hydroxy, 3-(2,3-dioxypropyl), bis-DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-8-[(2,2-ditert-butyl-1,3,2-dioxasilolan-4-yl)methyl]-1,3,2-benzodioxasilin-4-one. Molecular Formula: C26H44O5Si2. Molecular Weight: 492.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Medicare Quarterly Part B Spending by Drug

The Medicare Quarterly Part B Spending by Drug dataset presents information on spending for drugs administered in doctors’ offices and other outpatient settings by physicians and other healthcare providers to Medicare Part B enrollees. It also includes consumer-friendly descriptions of the drug uses, clinical indications, and manufacturer(s). 

 

Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability. All Part B drug spending metrics are calculated at the HCPCS level.

 

This dataset reports preliminary data that goes beyond the latest date available in the annual Medicare Part B Spending by Drug dataset. The data are updated each quarter and may change with each new release due to claims lag. Once an entire year of data is available with a sufficient run-out period, that data will move out of the preliminary quarterly dataset and into the annual Medicare Part B Spending by Drug dataset. Due to the preliminary nature of the quarterly dataset, we advise using caution when comparing between the annual and quarterly datasets.
Publications Using SAMHSA DataNational Survey of Substance Abuse Treatment Services (N-SSATS): 2017, Data on Substance Abuse Treatment Facilities

This report presents results from the 2017 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other jurisdictions. It is important to note that values in charts, narrative lists, and percentage distributions are calculated using actual raw numbers and rounded for presentation in this report; calculations using rounded values may produce different results.
NNDSS - TABLE 1K. Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection to Ehrlichia chaffeensis infection

NNDSS - Table 1K. Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection to Ehrlichia chaffeensis infection - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html 

Footnotes: 
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 529371: Ethyl 4-(2-iodo-3-methylbutanoyl)-3,5-dimethyl-1H-pyrrole-2-carboxylate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-(2-methylpropoxycarbonylamino)-3-(2-methylpropoxycarbonyloxy)propanoate. Molecular Formula: C19H37NO7Si. Molecular Weight: 419.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Public Health Reporting

The Centers for Medicare &amp; Medicaid Services (CMS) EHR Incentive Program provides incentive payments for eligible hospitals to adopt and meaningfully use certified health IT. Among the requirements to receive an incentive payment, participating hospitals must report on public health measures. These measures include the electronic reporting of data regarding: immunizations, emergency department visits (syndromic surveillance), reportable infectious disease laboratory results, and electronic patient data to specialized registries, like cancert. As of 2015, stage 2 of the EHR Incentive Program requires hospitals to report on three public health measures, when applicable, and modified stage 2 of the program requires hospitals to report on two of the three measures. This dataset includes the percentage of hospitals who reported on these measures in program years, 2013, 2014 and 2015.
Patent AT-E399785-T1: [Translated] NEW DERIVATIVES OF FLAVONE-C GLYCOSIDE AND COMPOSITION CONTAINING THESE DERIVATIVES

The present invention relates to novel flavone C-glycoside derivatives or salts thereof, especially those showing an anti-allergic effect, and compositions containing them. Recently, cases of allergic diseases, especially pollenosis and atopic dermatitis have increased to such a degree that they have become a social problem. Flavones and their glycosides have been reported to have the effect of inhibiting histamine release from mast cells or an immunosuppressive effect and expected for application as allergy therapies. However, most flavones exhibit their effects only at high doses, so that effective compounds at lower doses are highly desired. The present invention provides novel components capable of treating allergic diseases at low doses and compositions containing them.
National Health Interview Survey

2019–present. The National Health Interview Survey (NHIS) is a nationally representative household health survey of the U.S. civilian noninstitutionalized population. The NHIS data are used to monitor trends in illness and disability, track progress toward achieving national health objectives, for epidemiologic and policy analysis of various health problems, determining barriers to accessing and using appropriate health care, and evaluating Federal health programs. NHIS is conducted continuously throughout the year by the National Center for Health Statistics (NCHS). Public-use data files on adults and children with corresponding imputed income data files, and survey paradata are released annually. The NHIS data website (https://www.cdc.gov/nchs/nhis/documentation/index.html) features the most up-to-date public-use data files and documentation for downloading including questionnaire, codebooks, CSV and ASCII data files, programs and sample code, and in-depth survey description. Most of the NHIS data are included in the public use files. NHIS is protected by Federal confidentiality laws that state the data collected by NCHS may be used only for statistical reporting and analysis. Some NHIS variables have been suppressed or edited in the public use files to protect confidentiality. Analysts interested in using data that has been suppressed or edited may apply for access through the NCHS Research Data Center at https://www.cdc.gov/rdc/. In 2019, NHIS launched a redesigned content and structure that differs from its previous questionnaire designs. NHIS has been conducted continuously since 1957.
Compound 525401: Pentafluoropropionic acid, hexadecyl ester

Chemical compound data from PubChem database. IUPAC Name: hexadecyl 2,2,3,3,3-pentafluoropropanoate. Molecular Formula: C19H33F5O2. Molecular Weight: 388.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525118: 3-Chloropropyl isopentanoate

Chemical compound data from PubChem database. IUPAC Name: 3-chloropropyl 3-methylbutanoate. Molecular Formula: C8H15ClO2. Molecular Weight: 178.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Maltreatment 2019

This report presents national data about child abuse and neglect known to child protective services agencies in the United States during federal fiscal year 2019.

Letter from the Associate Commissioner

Acknowledgements

30th Edition of Child Maltreatment

Summary

CHAPTER 1: Introduction

CHAPTER 2: Reports

CHAPTER 3: Children

CHAPTER 4: Fatalities

CHAPTER 5: Perpetrators

CHAPTER 6: Services

CHAPTER 7: Special Focus

APPENDIX A: CAPTA Data Items

APPENDIX B: Glossary

APPENDIX C: State Characteristics

APPENDIX D: State Commentary

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 527158: 10-Hydroxycalamenene

Chemical compound data from PubChem database. IUPAC Name: (5-methyl-8-propan-2-yl-5,6,7,8-tetrahydronaphthalen-2-yl)methanol. Molecular Formula: C15H22O. Molecular Weight: 218.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 State Profile Report - Hawaii

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Compound 529484: 3-Hydroxy-4-oxo-2,3-dihydropyran-6-carbaldehyde

Chemical compound data from PubChem database. IUPAC Name: 3-hydroxy-4-oxo-2,3-dihydropyran-6-carbaldehyde. Molecular Formula: C6H6O4. Molecular Weight: 142.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Nursing Home Cost Report (RHCF): 2013

The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends.
2015 CMHS Uniform Reporting System (URS) Table for Louisiana

2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Louisiana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Availability of fiscal year (FY) 2023 funds under the Community-Based Grants for the Prevention of Child Abuse and Neglect program created by Title II of the Child Abuse Prevention and Treatment Act (CAPTA) as amended by Public Law (P.L.) 115-271

This Program Instruction sets forth the requirements for recipients of Community-Based Grants for the Prevention of Child Abuse and Neglect awards for FY 2023; and (2) provide guidance and instructions for the preparation and submission of the application and annual reports.

Metadata-only record linking to the original dataset. Open original dataset below.
Tafluprost

Tafluprost Ophthalmic (brand name Zioptan) is a prescription eye drop medication containing the active ingredient tafluprost, a prostaglandin analog. It works by increasing fluid drainage from the eye to lower intraocular pressure, commonly used to treat glaucoma or ocular hypertension. Apply one drop to the affected eye(s) once daily. This information was generated using AI and is provided for informational and research purposes only.
Compound 525174: Octaethylene glycol, diacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-[2-[2-(2-acetyloxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl acetate. Molecular Formula: C20H38O11. Molecular Weight: 454.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E40108-T1: [Translated] PROCESSES FOR THE PREPARATION OF PHARMACEUTICALLY ACTIVE ARYLOXYPROPANOLAMINE COMPOUNDS.

(57) A process for the preparation of an aryloxypropanolamine of the formulawherein Ar is a carbocyclic or heterocyclic aromatic group and R is an alkyl or substituted alkyl group having 1 to 6 carbon atoms, characterized in subjecting a compound of the formulato oxidative deavage to a dialdehyde of the formulawhich is then made subject to reduction, amination, acetal hydrolysis, and, where required, removal of a nitrogen protective group, to the formation of a compound of formula I, or an acid accition salt thereof, a compound of formula II and the preparation thereof from mannitol.
Patent AT-E401044-T1: [Translated] ARRANGEMENT FOR MITRAL VALVE THERAPY

An assembly for effecting the condition of a mitral valve of a heart includes a mitral valve therapy device, a guide wire, and a guide tube. The mitral valve therapy device is configured to reshape the mitral valve annulus of the heart when placed within the coronary sinus adjacent the mitral valve annulus. The guide wire is configured to be fed into the coronary sinus of the heart adjacent the mitral valve annulus. The guide tube has a distal end, a proximal end, and a lumen extending between the distal end and the proximal end. The guide tube further includes a side port, intermediate the distal and proximal ends which communicates with the lumen. This permits the guide tube to be slidingly received on the guide wire with the guide wire extending from the distal end, through the lumen, and out the side port. In use, the guide tube is slid along the guide wire into the coronary sinus. The mitral valve therapy device is then delivered by the guide tube into the coronary sinus adjacent the mitral valve annulus.
Provider Network Data: 2022 Quarter 4

This Provider Network Data contains information on individual and institutional providers participating in health plan networks from October through December 2022. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.

For more information, please visit: <a href=https://pndslookup.health.ny.gov>https://pndslookup.health.ny.gov</a>
Compound 528993: Heptadecane, 1,2-bis(methylthio)

Chemical compound data from PubChem database. IUPAC Name: 1,2-bis(methylsulfanyl)heptadecane. Molecular Formula: C19H40S2. Molecular Weight: 332.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Inotuzumab ozogamicin

Besponsa (inotuzumab ozogamicin) is an intravenous prescription drug, supplied as a lyophilized powder for injection. It's an immunoconjugate that targets CD22 on cancer cells, leading to DNA damage and cell death. Manufactured by Wyeth Pharmaceuticals LLC (a Pfizer subsidiary), it's used in treating relapsed or refractory acute lymphoblastic leukemia. This information was generated using AI and is provided for informational and research purposes only.
Cardiac rehabilitation: a comprehensive review

Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR. Numerous individual studies, however, have demonstrated beneficial effects such as improved risk-factor profile, slower disease progression, decreased morbidity, and decreased mortality. This paper will review the evidence for the use of CR and discuss the implications and limitations of these studies. The safety, relevance to special populations, challenges, and future directions of CR will also be reviewed.
Supracervical hysterectomy versus total abdominal hysterectomy: perceived effects on sexual function

Background
          Our investigation sought to compare changes in sexual function following supracervical hysterectomy (SCH) and total abdominal hysterectomy (TAH).
        
        
          Methods
          A retrospective chart review was performed to identify all patients who underwent supracervical hysterectomy or total abdominal hysterectomy at a tertiary care center. Patients who met criteria for participation were sent a one page confidential, anonymous questionnaire to assess sexual function experienced both pre- and postoperatively. A total of 69 patients in each group were eligible for participation. A multiple logistic regression model was used to analyze measured variables.
        
        
          Results
          Forty-eight percent (n = 33) of women undergoing a SCH returned the questionnaire, while 39% (n = 27) of those undergoing a TAH chose to participate. There were no significant demographic differences between the two groups. Patients who underwent TAH reported worse postoperative sexual outcome than SCH patients with respect to intercourse frequency, orgasm frequency and overall sexual satisfaction (P = 0.01, 0.03, and 0.03, respectively). Irrespective of type of hysterectomy, 35% of patients who underwent bilateral salpingoophorectomy (BSO) with hysterectomy experienced worse overall sexual satisfaction compared to 3% of patients who underwent hysterectomy alone (P = 0.02).
        
        
          Conclusions
          Our data suggest that TAH patients experienced worse postoperative sexual function than SCH patients with respect to intercourse frequency and overall sexual satisfaction. Irrespective of type of hysterectomy, patients who underwent bilateral salpingoophorectomy experienced worse overall sexual satisfaction.
NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b

NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
 Max: Maximum — Maximum case count during the previous 52 weeks.
  * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).